

CURRICULUM VITAE JAVIER CRESPO**Full name:**

- Javier Crespo García.
- Unique researcher identifier: <https://orcid.org/0000-0001-8248-0172>
- Mail:
 - o javier.crespo@scsalud.es
 - o Javiercrespo1991@gmail.com

Research: Director of the Research group in Marqués de Valdecilla Research Institute (IDIVAL-HUMV) and Head of the clinical group associated with CIBERehd (GVC16 / EHD / 4), a multidisciplinary and transversal group that includes biologists, biotechnologists, chemists, nurses, and physicians among its components. Stable research lines in viral hepatitis (more than 25 years, I began with my doctoral thesis I read in 1993) and NASH (I started in 2001 with the publication of an original manuscript in Hepatology), I was a translational research study. I have experience in the management of multi-center projects. At this moment, our group is part of: the core of the Spanish Registry of Metabolic Associated Liver Disease (HEPAMET), the CIBERehd, the European consortium LITMUS for the study of NASH, we participate in more than 20 international clinical trials phase II and III. Moreover, we are running several research projects. I have broad experience in clinical and translational research. I have participated in more than 75 clinical trials phases I to III in HCV, and HBV. I have published more than 230 articles in peer reviewed journals. I have contributed with more than 400 abstracts presented in national and international meetings. I have been granted with several R+D+I projects from public and private calls. I have given more than 100 presentations in national and international courses in liver diseases. I am an author in different guidelines and consensus in gastroenterology and hepatology. I have been a director and co-director in more than 20 national and international courses.

Academic records:

- Bachelor of Medicine. October 1985. Qualification: Outstanding.
- Degree of Doctor Medicine. October 1993. School of Medicine of the University of Cantabria. Extraordinary Doctorate Award.

Current positions:

- Head of the Gastroenterology and Hepatology Unit. University Hospital Marqués de Valdecilla.
- Head of the Digestive Diseases Research Group in the Marqués de Valdecilla Research Institute (IDIVAL).
- Professor of Medicine at the University of Cantabria.
- President of the National Commission of the Digestive Specialty.
- President of the Spanish Society of Digestive Diseases (SEPD).

Other merits:

- Member of the Strategic Plan of the National Health System to tackle hepatitis C infection.
- National and international evaluator and reviewer for different international journals and research scholarship programs.
- Commendation of the Civil Health Order. 2016
- Best in Class Award 2014 - 2018. Best Digestive Service in Spain.
- Best in Class Award 2015 - 2019. Best Hepatitis C Care Service in Spain.

Areas of interest: Hepatitis C (HCV) / Hepatitis B (HBV) / Non-alcoholic steatohepatitis (NAFLD, NASH, MAFLD)

Research experience:

- Original articles published: More than 250
- Chapters of books or complete books: 50.
- Communications to congresses (national and international): More than 500.
- Conferences and invited papers (national and international): More than 120.
- Clinical trials conducted: More than 75 trials phase I to III.

- Competitive funded research projects: 19
- Six-year research periods: 4
- PhD thesis supervised: 8
- PhD thesis ongoing: 8
- Total citations: >14.300

Articles published in the last three years (January 2019- January 2022)

1. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocamo P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol.* 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27. PMID: 34707258. **IF: 46.802. D1**
2. da Silva Lima N, Fondevila MF, Nóvoa E, Buqué X, Mercado-Gómez M, Gallet S, González-Rellán MJ, Fernandez U, Loyens A, Garcia-Vence M, Chantada-Vazquez MDP, Bravo SB, Marañón P, Senra A, Escudero A, Leiva M, Guallar D, Fidalgo M, Gomes P, Claret M, Sabio G, Varela-Rey M, Delgado TC, Montero-Vallejo R, Ampuero J, López M, Diéguez C, Herrero L, Serra D, Schwaninger M, Prevot V, Gallego-Duran R, Romero-Gomez M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Garcia-Monzon C, Gonzalez-Rodriguez A, Aspichueta P, Nogueiras R. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. *J Hepatol.* 2022 Jan;76(1):11-24. doi: 10.1016/j.jhep.2021.09.008. Epub 2021 Sep 21. PMID: 34555423. **IF: 25.083 (2/92 in Gastroenterology & Hepatology). D1, Q1**
3. Santos-Laso A, Gutiérrez-Larrañaga M, Alonso-Peña M, Medina JM, Iruzubieta P, Arias-Loste MT, López-Hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. *Biomedicines.* 2021 Dec 26;10(1):46. doi: **D1**
4. Crespo J, Iruzubieta P, Lazarus JV. Can NAFLD overwhelm the Spanish healthcare system in the years to come? *Rev Esp Enferm Dig.* 2022 Jan;114(1):5-9. doi: 10.17235/reed.2021.8524/2021. PMID: 34962132.
5. Gutiérrez-Larrañaga M, González-López E, Roa-Bautista A, Rodrigues PM, Díaz-González Á, Banales JM, López-Hoyos M, Santos-Laso A, Crespo J. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? *Liver Cancer.* 2021 Sep 21;10(6):545-560. doi: 10.1159/000518104. PMID: 34950178; PMCID: PMC8647071. **D1**
6. Ampuero J, Aller R, Gallego-Durán R, **Crespo J**, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Agustín S, Pareja-Megía MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. *Liver Int.* 2021 Sep;41(9):2076-2086. doi: 10.1111/liv.14898. Epub 2021 May 7. PMID: 33896100. **IF: 5.828 (25/92 Gastroenterology & Hepatology). Q2**
7. Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, San-Segundo D, Merino D, Cuadrado A, Vaqué JP, López-Hoyos M, Crespo J. Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFN γ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. *Viruses.* 2021 Apr 7;13(4):635. doi: 10.3390/v13040635. PMID: 33917265; PMCID: PMC8068025. **IF: 5.048 Q2 Virology**
8. Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. *Diagnostics (Basel).* 2021 May 14;11(5):877. doi: 10.3390/diagnostics11050877. PMID: 34068955; PMCID: PMC8155928. **IF 3.706 Q2 (Internal Medicine)**
9. Cabezas J, Llerena S, Crespo J. Telemedicine, time to change paradigm of Hepatitis C management: improve access and reduce costs. *Rev Esp Enferm Dig.* 2021 Feb 11. doi: 10.17235/reed.2021.7809/2021. Epub ahead of print. PMID: 33569962. **IF, 2. 01, Q4**

10. Colom C; Torrens M; Rodríguez-Cejas A; Aguilar I; Álvarez-Crespo R; Armenteros L; Ayala V; Cantero H; Casado MA; Crespo J; Estévez J; García-Samaniego J; Hernández-Guerra M; Mur C; Pérez-Bech E; Ricote M; Pineda JA. Programa de certificación de Centros de Adicciones para la eliminación del virus de la hepatitis C en España. Proyecto HepCelentes. Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes Project. Adicciones 2021 In press. IF: 1.722, Q4
11. Crespo J, Iruzubieta P, Lazarus JV. Can NAFLD overwhelm the Spanish healthcare system in the years to come?. REED 2022; in press. Servicio. IF, 2.01, Q4
12. Crespo J, Lazarus JV, Iruzubieta P, García F, García-Samaniego J; Alliance for the Elimination of Viral Hepatitis in Spain. Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. J Hepatol. 2021 Jul;75(1):224-226. doi: 10.1016/j.jhep.2021.03.009. Epub 2021 Mar 20. PMID: 33757805; PMCID: PMC7979603. IF: 25.083 (2/92 in Gastroenterology & Hepatology). D1, Q1
13. Crespo J, Díaz-González Á, Cabezas J. HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination? J Hepatol. 2021 May 7:S0168-8278(21)00308-1. doi: 10.1016/j.jhep.2021.04.043. Epub ahead of print. PMID: 33971225; PMCID: PMC8103740. Servicio. IF: 25.083 (2/92 in Gastroenterology & Hepatology). D1, Q1
14. Crespo J; on behalf of the Grupo técnico de cribado de la infección por el VHC. Screening guide for hepatitis C virus infection in Spain. REV ESP ENFERM DIG 2021;113(2):81-82DOI: 10.17235/reed.2020.7728/2020. IF, 2.01, Q4
15. Cuadrado A, Gaité LM, Odriozola A, Oloriz R, Herrera S, Fortea JI, Amigo L, Anderson EJ, Artal JA, Crespo J, Fábrega E. Impact of the COVID-19 lockdown on liver transplant recipients. A single center observational study. Rev Esp Enferm Dig. 2021 Sep 2. doi: 10.17235/reed.2021.8173/2021. Epub ahead of print. PMID: 34470450. Servicio. IF, 2.01, Q4
16. Cuadrado A, Cobo C, Mateo M, Blasco AJ, Cabezas J, Llerena S, Fortea JI, Lázaro P, Crespo J. Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. Int J Drug Policy. 2020 Nov 19;88:103031. doi: 10.1016/j.drugpo.2020.103031. Epub ahead of print. PMID: 33221615. IF: 5.009. Q2
17. Cuadrado A, del Barrio M, Fortea I, Amigo L, SanSegundo D, Rodriguez MP, Rebollo MH, Fernandez R, Castillo FJ, Achalanda MM, Echeverri JA, Anderson EJ, Rodriguez-SanJuna JC, Lopez-Hoyos M, Crespo J, Fábrega E. Antibody Response to the mRNA-1273 vaccine (Moderna) in Liver Transplant Recipients" has been received by our editorial office. Liver Transplantation 2021. For future correspondence, please refer to the manuscript identification number LT-21-790, Impact factor: 5.799; (4/25 Transplantation) Q1
18. da Silva Lima N, Fondevila MF, Nóvoa E, Buqué X, Mercado-Gómez M, Gallet S, González-Rellán MJ, Fernandez U, Loyens A, Garcia-Vence M, Chantada-Vazquez MdP, Bravo SB, Marañón P, Senra A, Escudero A, Leiva M, Guallar D, Fidalgo M, Gomes P, Claret M, Sabio G, Varela-Rey M, Delgado TC, Montero-Vallejo R, Ampuero J, López M, Diéguez C, Herrero L, Serra D, Schwaninger M, Prevot V, Gallego-Duran R, Romero-Gomez M, Iruzubieta P, Crespo J, Martinez- Chantar ML, Garcia-Monzon C, Gonzalez-Rodriguez A, Aspichueta P, Nogueiras R, Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function, Journal of Hepatology (2021), doi: <https://doi.org/10.1016/j.jhep.2021.09.008>. IF: 25.083 (2/92 in Gastroenterology & Hepatology). D1, Q1
19. Fondevila MF, Mercado-Gómez M, Rodríguez A, Gonzalez-Rellán MJ, Iruzubieta P, Valentí V, Escalada J, Schwaninger M, Prevot V, Dieguez C, Crespo J, Frühbeck G, Martinez-Chantar ML, Nogueiras R. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol. 2021;74:469-471.F.I.:20,582. [doi:10.1016/j.jhep.2020.09.027]. Impact Factor: 25.083 (2/92 in Gastroenterology & Hepatology). D1, Q1
20. Francque SM, Bedossa P, Ratzu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhoury N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. ([Sven Francque](#), [Nicolas Lanthier](#), [Christophe Moreno](#), [Anja Geerts](#), [Geert Robaey](#), [Elisabetta Bugianesi](#), [Antonio Craxi](#), [Pietro Lampertico](#), [Alessandra Mangia](#), [Vlad Ratzu](#), [Aline Le Cleach](#), [Jérôme Boursier](#), [Rodolph Anty](#), [Albert Tran](#), [Vincent Di Martino](#), [Maeva Guillaume](#), [Christophe Bureau](#), [Victor De Ledinghen](#), [Dominique Larrey](#), [Massimo Levrero](#), [Vincent Leroy](#), [Charlotte Costentin](#), [Laurent Castera](#), [Christophe Hezode](#), [Anne](#)

- [Varaut, Lawrence Serfaty, Quentin Antsee, Stuart Mcpherson, Stephen Ryder, Kosh Agarwal, Jean-François Dufour, Benedetta Terziroli, Manuel Romero Gomez, Javier Crespo, José Luis Calleja, Salvador Augustin, Anna Piekarska, Krzysztof Tomasiewicz, Piotr Napora, Jörn Schattenberg, Uta Merle, Christian Trautwein, Tobias Boettler, Hauke Heinzow, Petr Urbanek, Jan Sperl, Vaclav Hejda, Michael Trauner, Alex Hodge, Damian Harding, Richard Skoien, Kate Muller, Oyekoya Ayonrinde, Giada Sebastiani, Laura Stinton, Paula Marotta, Etienne Desilets, Régine Rouzier, Lyudmila Mateva, Rozalina Balabanska, Bozhidar Tomov, Diana Stefanova-, Petrova Petrova, Stoyan Handzhiev, Guy Neff, Arun Khazanchi, Stephen Harrison, Stephen Caldwell, Donald Lazas, Arun Sanyal, Manal Abdelmalek, Naim Alkhouri, Jorge Castaneda, Rohit Loomba, Parvin Syal, Mark Leibowitz, Matthew Myers, Michael Brown, Miran Geric.](#) A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. *N Engl J Med.* 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. PMID: 34670042. **IF: 91.245, D1, Q1**
21. Lazarus JV, Picchio CA, Byrne C, Crespo J, Colombo M, Cooke G, Dore García MJ, Rivero M.; Miranda-Bautista, J.; Bastón-Rey, I.; Mesonero, F.; Leo-Carnerero, E.; Casas-Deza, D.; Cagigas Fernández, C.; Martin-Cardona, A.; El Hajra, I.; et al. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. *J. Clin. Med.* 2021, 10, 4402. <https://doi.org/10.3390/jcm10194402> **Impact Factor of 5.583. 15/154 (Q1) in 'Medicine, General & Internal.'**
 22. González-Romero F, Mestre D, Aurrekoetxea I, O'Rourke CJ, Andersen JB, Woodhoo A, Tamayo-Caro M, Varela-Rey M, Palomo-Irigoyen M, Gómez-Santos B, de Urturi DS, Núñez-García M, García-Rodríguez JL, Fernández-Ares L, Buqué X, Iglesias-Ara A, Bernales I, De Juan VG, Delgado TC, Goikoetxea-Usandizaga N, Lee R, Bhanot S, Delgado I, Perugorria MJ, Errazti G, Mosteiro L, Gaztambide S, Martínez de la Piscina I, Iruzubieta P, Crespo J, Banales JM, Martínez-Chantar ML, Castaño L, Zubiaga AM, Aspichueta P. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. *Cancer Res.* 2021 Jun 1;81(11):2874-2887. doi: 10.1158/0008-5472.CAN-20-2052. Epub 2021 Mar 26. PMID: 33771899. **IF: 12.701, D1, Q1**
 23. Guerra Ruiz AR, Crespo J, López Martínez RM, Iruzubieta P, Casals Mercadal G, Lalana Garcés G, Lavín B, Morales Ruiz M. MEDICIÓN Y UTILIDAD CLÍNICA EN LA ENFERMEDAD HEPÁTICA. *Advances in Laboratory Medicine* 2021.
 24. Guerra Ruiz AR, Casals Mercadal G, Iruzubieta P, Lalana Garcés M, Leis A, López Martínez RM, Crespo J, Morales Ruiz M. Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. *De Gruyter* | 2020 DOI: <https://doi.org/10.1515/almed-2020-0062>. *Advances in Laboratory Medicine* 2021.
 25. Gutiérrez-Larrañaga M, Gonzalez-Lopez E, Roa AA, Banales JM, López-Hoyos M, Santos-Laso A, Crespo J. Immune checkpoint inhibitors: the emerging cornerstone in cholangiocarcinoma therapy?. *Liver Cancer* 2021; 10(6): 545-560. doi: 10.1159/000518104. PMID: 34950178; PMCID: PMC8647071. **Servicio. Impact Factor: 11.740, D1, Q1**
 26. Iruzubieta P, Lazarus JV, Crespo J. SARS-CoV-2 detection by self-testing: a method that makes surveillance programs possible and effective. *Gastroenterol Hepatol.* 2021 Jan 27:S0210-5705(21)00006-6. English, Spanish. doi: 10.1016/j.gastrohep.2021.01.001. Epub ahead of print. PMID: 33515624; PMCID: PMC7840430. **IF: 2,1 / Q4**
 27. Iruzubieta P, Arias-Loste MT, Fortea JI, Cuadrado A, Rivas-Rivas C, Rodríguez-Duque JC, García-Ibarbia C, Hernández JL, Crespo J. National Digestive Disease Specialists Survey on Cardiovascular Risk Management in Non-Alcoholic Fatty Liver Disease in Spanish hospitals. *Liver Int.* 2021 Feb 1. doi: 10.1111/liv.14807. Epub ahead of print. PMID: 33527637. **IF: 5.828 / 25/92 (Gastroenterology & Hepatology) Q2**
 28. Iruzubieta P, Goikoetxea-Usandizaga N, Barbier-Torres L, Serrano-Maciá M, Fernández-Ramos M, Pablo Fernández-Tussy, Virginia Gutiérrez-de-Juan, Sofia Lachiondo-Ortega, Jorge Simon, Miren Bravo, Fernando Lopitz-Otsoa, Mercedes Robles, Carlos Ferre-Aracil, Marta Varela-Rey, Natalia Elguezabal, José Luis Calleja, Shelly C Lu, Malgorzata Milkiewicz, Piotr Milkiewicz, Juan Anguita, María J Monte, José J G Marin, Marcos López-Hoyos, Teresa C. Delgado, Mercedes Rincón, Javier Crespo, María Luz Martínez-Chantar. Boosting mitochondrial activity by silencing MCJ overcomes cholestasis-induced liver injury. *J Hepatol Report* 2021
 29. Iruzubieta P, Fernández-Lanas T, Rasines L, Cayon L, Álvarez-Cancelo A, Santos-Laso A, García-Blanco A, Curiel-Olmo S, Cabezas J, Wallmann R, Fábrega E, Martínez-Taboada VM, Hernández JL, López-Hoyos M, Lazarus JV, Crespo J. Feasibility of large-scale population testing for SARS-

- CoV-2 detection by self-testing at home. *Sci Rep.* 2021 May 10;11(1):9819. doi: 10.1038/s41598-021-89236-x. PMID: 33972607; PMCID: PMC8110575. **IF: 5,01 / Q1**
30. Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. *Front Immunol.* 2021 Mar 30;12:651728. doi: 10.3389/fimmu.2021.651728. PMID: 33859644; PMCID: PMC8042647. **IF: .7,561; D1**
 31. Lavín-Alconero L, Fernández-Lanas T, Iruzubieta-Coz P, Arias-Loste MT, Rodríguez-Duque JC, Rivas C, Cagigal ML, Montalbán C, Useros AL, Álvarez-Cancelo A, García-Saiz M, Crespo-García J. Efficacy and safety of endoscopic sleeve gastropasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). *Trials.* 2021; 22: 756. doi: 10.1186/s13063-021-05695-7. PMID: 34717726; PMCID: PMC8556907. **IF: 2,049 / Q4**
 32. Lazarus JV, Bassat Q, Crespo J, Fanjul G, Garcia-Basteiro AL; López Hoyos M, Mateos C, Muñoz Gutierrez J, Naniche D, Oliu-Barton M, Rabin KH, Vilasanjuan R, Villapol S, Martin-Moreno JM. Vaccinate fast but leave no one behind: a call to action for COVID-19 vaccination in Spain. *Communications Medicine* 2021. <https://doi.org/10.1038/s43856-021-00014-2>.
 33. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocamo P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol.* 2021 Oct 27. doi: 10.1038/s41575-021-00523-4. Epub ahead of print. PMID: 34707258. **IF: 46.802. D1**
 34. Lopez-Gomez M, Llop E, Puente A, Hernández Conde M, Ruiz P, Álvarez S, Martínez JL, Abad J, Fernández N, Perelló C, Fernández-Carrillo C, Ferre C, Trapero M, Fraga E, Crespo J, Calleja Panero JL. Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. *Hepatol Res.* 2021; 51(10): 1064-1072. doi: 10.1111/hepr.13703. Epub 2021 Aug 17. PMID: 34324766. **IF: 4.288 Q2.** 39/92 (*Gastroenterology & Hepatology*).
 35. Llop E, Iruzubieta P, Perelló C, Fernández Carrillo C, Cabezas J, Escudero MD, González M, Hernández Conde M, Puchades L, Arias-Loste MT, Serra MÁ, Crespo J, Calleja JL. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. *United European Gastroenterol J.* 2021 Jun 2. doi: 10.1002/ueg2.12109. Epub ahead of print. PMID: 34077628. Impact factor: 4.623. Q2. 34/92 (*Gastroenterology & Hepatology*). **IF: 4.623 / Q2**
 36. Marcos-Fosch C, Cabezas J, Crespo J, Buti M, Anti-epileptic drugs and hepatitis C therapy: real world experience, *J Hepatology* 2021, doi: <https://doi.org/10.1016/j.jhep.2021.05.040>. **IF: 25.083, D1.** 2 out of 92 in *Gastroenterology & Hepatology*
 37. Medina JM, Fernández-López R, Crespo J, Cruz F. Propionate Fermentative Genes of the Gut Microbiome Decrease in Inflammatory Bowel Disease. *J Clin Med.* 2021; 10(10): 2176. doi: 10.3390/jcm10102176. PMID: 34070019. **IF: 4.567 Q1 (Medicine, General & Internal)**
 38. Newsome PN, Kristine Buchholtz¹, Kenneth Cusi¹, Martin Linder¹, Takeshi Okanoue¹, Vlad Ratziu¹, Arun J Sanyal¹, Anne-Sophie Seiling¹, Stephen A Harrison¹, NN9931-4296 Investigators Jacob George, Martin Weltman, Marno Ryan, Amanda Nicoll, Hermann Toplak, Bernhard Ludvik, Elmar Aigner, Sven Francque, Anja Geerts, Yves Horsmans, Christophe Moreno, Rozalina Balabanska, Lyudmila Mateva Vladimirova, Meredith Borman, Saumya Jayakumar, Magnus McLeod, Gerald Minuk, Marco Puglia, Giada Sebastiani, Peter Ghali, Scott Fung, Mady Elkhatab, Tisha Joy, Naresh Aggarwal, Henning Gronbæk, Lise Lotte Gluud, Hannele Yki-Järvinen, Rodolphe Anty, Marc Bourliere, Dominique Larrey, Marianne Maynard-Muet, Lionel Wander, Vlad Ratziu, Victor de Ledinghen, Maeva Guillaume, Christophe Bureau, George Papatheodoridis, Georgios Germanidis, George Dalekos, Emmanouil Sinakos, Spyridon Dourakis, Kazuo Notsumata, Kojiro Mori, Yoshito Itoh, Toshihide Shima, Masayoshi Horimoto, Keizo Anzai, Shigetoshi Fujiyama, Koichi Takaguchi, Masashi Yoneda, Hideki Fujii, Hirayuki Enomoto, Satoyoshi Yamashita, Shiro Takami, Elena Vinnitskaya, Igor G Bakulin, Viktor D Pasechnikov, Tatiana A Milovanova, Marina F Osipenko, Lubov V Kargina, Marina Y Sergeeva-Kondrachenko, Tatyana A Lysenko, Anna R Volkova, Emma A Voychik, Larisa A Rogova, Alexey P Zharkov, Tatiana V Stepanova, Elena V Frolova, Dmitriy V Pasechnikov, Olga V Trofimova, Andrey B Peskov, Marina A Kunitsyna, Anna V

- Belkovets, Maria V Matsievich, Yuriy Y Poteshkin, Olga I Mishchenko, Lidia V Belousova, Leylya R Gaysina, Diana N Alpenidze, Elizaveta Antonova, M Romero Gómez, J Calleja, S Benlloch, J Crespo Garcíá, A Albillos Martínez, S Tomé, Per Stål, Joanna Uddén Hemmingsson, Johan Farngren, J P H Drenth, G H Koek, T C M A Schreuder, H Blokzijl, M E Tushuizen, M Klemm-Kropp, M Nieuwdorp, Philip Newsome, Jude Oben, Michael Allison, Lynsey Corless, Ewan Forrest, Peter Hayes, Michael Miller, Mahesh Bhalme, Guru Aithal, Lee Claridge, Andrew Austin, Emmanuel Tsochatzis, Andrew King, Kosh Agarwal, Chin Lye Ch'ng, Kenneth Cusi, Eugene Schiff, William Timothy Garvey, Tarek I Hassanein, Christopher D Still, Scott Overcash, Charles Landis, Gholamreza Bonabi, Isaac Beshay, Victor Ankoma-Sey, Heidi A Kabler, Gregory T Sholeff, Hoa-Tuyet Thi Ami Bui, Elliot E Shin, David E Bernstein, Grisell Ortiz Lasanta, Juan Pablo Frias, Julio Rosenstock, Joseph E Pouzar, Stephen Harrison, Ildiko Lingvay, Cyrus Desouza, Zeid Kayali, Stephanie Shaw, Syed-Mohammed Jafri, Anurag Maheshwari, Miguel Malespin, Bal Raj Bhandari, Sam E Moussa, Mordechai Rabinovitz, Seth J Baum, Nadege T Gunn, Kevin R Finnegan, Ann Moore, Arun Khazanchi, Robert Allen Jenders, William Kelly Bowman, Kenneth C Lasserter. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med.* 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. **IF: 91.245, D1, Q1**
39. Picchio CA, Lens S; Hernandez-Guerra M; Arenas J; Andrade RA; Crespo J; García-Samaniego J; Romero M; Turnes J; Calleja JL; Simón MA; White TM; Riveiro-Barciela M; Pocurull A; Morales-Arreaez D; Gómez A; Buti M; Lazarus JV. Late presentation to care in chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) patients seeking first time specialist care in Spain: a two-year registry review. *Scientific Report* 2021; 11: 24133 | <https://doi.org/10.1038/s41598-021-01885-0> **IF: 5.133; Q2**
40. Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut.* 2021 Mar 19;gutjnl-2020-323663. doi: 10.1136/gutjnl-2020-323663. Epub ahead of print. PMID: 33741640. **IF: 23.059; D1.**
41. Serrano-Maciá M, Simón J, González-Rellan MJ, Azkargorta M, Goikoetxea-Usandizaga N, Lopitz-Otsoa F, De Urturi DS, Rodríguez-Agudo R, Lachiondo-Ortega S, Mercado-Gomez M, Gutiérrez de Juan V, Bizkarguenaga M, Fernández-Ramos D, Buque X, Baselli GA, Valenti LVC, Iruzubieta P, Crespo J, Villa E, Banales JM, Avila MA, Marin JJG, Aspichueta P, Sutherland J, Barrio R, Mayor U, Elortza F, Xirodimas DP, Nogueiras R, Delgado TC, Martínez-Chantar ML. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. *Mol Metab.* 2021; 53:101275. doi: 10.1016/j.molmet.2021.101275. Epub 2021 Jun 18. PMID: 34153521; PMCID: PMC8280515. **IF: 7.422, D1** ranking it 16 out of 145 in *Endocrinology & Metabolism*
42. Sicras-Mainar A, Aller R, Crespo J, Calleja JL, Turnes J, Romero Gómez M, Agustín S. Impacto clínico y económico global de la enfermedad hepática por hígado graso no alcohólico. *Rev Esp Enferm Dig* 2021;113(6):396-403 DOI: 10.17235/reed.2020.7238/2020. **IF: 2,01 / Q4**
43. Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: A cost-of-illness analysis. *Liver Int.* 2021 Feb 15. doi: 10.1111/liv.14825. Epub ahead of print. PMID: 33590598. **IF: 5.828, Q2**
44. Simón J, Goikoetxea-Usandizaga N, Serrano-Maciá M, Fernández-Ramos D, Sáenz de Urturi D, Gruskos JJ, Fernández-Tussy P, Lachiondo-Ortega S, González-Recio I, Rodríguez-Agudo R, Gutiérrez-de-Juan V, Rodríguez-Iruretagoyena B, Varela-Rey M, Gimenez-Mascarell P, Mercado-Gomez M, Gómez-Santos B, Fernandez-Rodriguez C, Lopitz-Otsoa F, Bizkarguenaga M, Dames S, Schaeper U, Martin F, Sabio G, Iruzubieta P, Crespo J, Aspichueta P, Chu KH, Buccella D, Martín C, Delgado TC, Martínez-Cruz LA, Martínez-Chantar ML. Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. *J Hepatol.* 2021

- Jul;75(1):34-45. doi: 10.1016/j.jhep.2021.01.043. Epub 2021 Feb 9. PMID: 33571553; PMCID: PMC8217299. **Impact Factor: 25.083 (2/92 in Gastroenterology & Hepatology). D1, Q1**
45. White TM, Cash-Gibson L, Martin-Moreno JM, Matesanz R, Crespo J, Alfonso-Sanchez JL, Villapol S, El-Mohandes A, Lazarus JV. COVID-SCORE Spain: Public perceptions of key government COVID-19 control measures. *European Journal of Public Health* 2021, **IF: 4.011 / Q2**
 46. Argüelles-Arias F, Crespo J, Calleja MÁ; en representación de la Sociedad Española de Patología Digestiva (SEPD), Fundación Española de Aparato Digestivo (FEAD) y de la Sociedad Española de Farmacia Hospitalaria (SEFH). Relación entre digestivos y farmacéuticos de hospital: resultados de una encuesta nacional. *Estudio CONDIFA. Rev Esp Enferm Dig* 2020; 112(9): 675-681 DOI: 10.17235/reed.2020.7131/2020
 47. Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, et al; HEPAmet Registry. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. *J Hepatol* 2020 Mar 6: S0168-8278 (20)30127-6. doi: 10.1016/j.jhep.2020.02.028. Online ahead of print. PMID: 32147361
 48. Barbier-Torres L, Fortner KA, Iruzubieta P, Delgado TC, Giddings E, Chen C, Champagne D, Fernández-Ramos D, Mestre D, Gomez-Santos B, Varela-Rey M, Gutiérrez de Juan M, Fernández-Tussy P, Zubiete-Franco I, García-Monzón C, González-Rodríguez A, Oza D, Valenca-Pereira F, Fang Q, Crespo J, Aspichueta P, Tremblay F, Christensen BC, Anguita , Martínez-Chantar ML, Rincón M. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. *Nat Commun.* 2020 Jul 3;11(1):3360. doi: 10.1038/s41467-020-16991-2.
 49. Cabezas J, García F, Calleja Panero JL, Buti M, Molero García JM, Blasco AJ, Lázaro de Mercado P, Crespo J. Principles for implementing a population screening strategy for hepatitis C in Spain. *Rev Esp Enferm Dig.* 2020; 112 (1): 64-70. doi: 10.17235/ reed. 2019. 6768/ 2019. PMID: 31880160
 50. Calleja-Panero JL, Andrade RJ, Bañares R, Crespo J, Esteban R, Jarque I, Mingot-Castellano ME, Romero-Gómez M, Muñoz-Peñín R, Bentley R, Shepherd J, Gil Aguirre A [Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts.](#) *Rev Esp Enferm Dig.* 2020 Sep 21;112. doi: 10.17235/reed.2020.6895/2020. Online ahead of print. PMID: 32954777
 51. Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. *Antiviral Res.* 2020 Feb;174:104694. doi: 10.1016/j.antiviral.2019.104694. Epub 2019 Dec 16. PMID: 31857134
 52. Crespo J, Cuadrado A, Perelló C, Cabezas J, Llerena S, Llorca J, Cedillo S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Lazarus JV, Calleja JL. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. *J Viral Hepat.* 2020 Apr;27(4):360-370. doi: 10.1111/jvh.13238. Epub 2019 Dec 6. PMID: 31755634
 53. Crespo J, Calleja JL, Zapatero A. Massive infection of healthcare professionals with SARS CoV-2 in Spain—Not by chance. *BMJ.*
 54. Crespo J; Fernández Carrillo C; Iruzubieta P; Hernández-Conde M; Rasines L; Jorquera F; Albillos A; Bañares R; Mora P; Fernández Vázquez I; Hernández-Guerra M; Turnes J; Calleja JL. MASSIVE IMPACT OF COVID-19 PANDEMIC ON GASTROENTEROLOGY AND HEPATOLOGY DEPARTMENTS AND DOCTORS IN SPAIN. *J Gastroenterology and Hepatology* 2020. In press.
 55. Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. *Enferm Infecc Microbiol Clin.* 2020 May 22;S0213-005X(20)30173-7. doi: 10.1016/j.eimc.2020.03.004.
 56. Crespo J, Andrade R, Alberca de Las Parras F, Balaguer F, Barreiro-de Acosta M, Bujanda L, Gutiérrez A, Jorquera F, Iglesias-García J, Sánchez-Yagüe A, Calleja JL. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. *Gastroenterol Hepatol.* 2020: S0210-5705(20)30134-5. doi: 10.1016/ j.gastrohep. 2020.04.001
 57. Crespo J, Iglesias-García J, Hinojosa Del Val JE, García García F, Gil de Miguel Á, Fernández Carrillo C, Ampuero J, Pérez-Cuadrado Martínez E. COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. *Rev Esp Enferm Dig.* 2020 May;112(5):389-396. doi: 10.17235/reed.2020.7128/2020. PMID: 32338017
 58. Crespo J, Carballo Álvarez F, Alberca de Las Parras F, Fernández Rodríguez CM, Vera Mendoza MI, Gómez M, Elola Somoza FJ. Digestive units in the National Health System of the 21st century.

- Organizational and management standards for a patient-centered service. *Rev Esp Enferm Dig.* 2020 Feb;112(2):144-149. doi: 10.17235/reed.2020.6778/2019.PMID: 31960697
59. Crespo J, Andrade R, Alberca de Las Parras F, Balaguer F, Barreiro-de Acosta M, Bujanda L, Gutiérrez A, Jorquera F, Iglesias-García J, Sánchez-Yagüe A, Calleja JL. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. *Rev Esp Enferm Dig.* 2020 May;112(5): 397-411. doi: 10.17235/reed.2020.7141/2020.PMID: 32316737
 60. Crespo J, Elola Somoza FJ. Author's reply: "Consensus document for Digestive services in the National Health System of the XXI century". *Rev Esp Enferm Dig.* 2020 Jun 24;112. doi: 10.17235/reed.2020.7257/2020. Online ahead of print.PMID: 32579002
 61. Cuadrado A, Perelló C, Cabezas J, Llerena S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Calleja JL, Crespo J. Update on epidemiology of hepatitis B in a low-endemic European country: there is still much to do. *J Viral Hepat.* 2020 Jun 19. doi: 10.1111/jvh.13350. Online ahead of print.
 62. Cuadrado A, Cabezas J, Llerena S, Nieves Salceda JF, Fortea JI, Crespo-Facorro B, Crespo J. Prevalence of hepatitis C in patients with non-affective psychotic disorders. *Rev Esp Enferm Dig.* 2020 Jun 24;112. doi: 10.17235/reed.2020.7278/2020. Online ahead of print.
 63. Cuadrado-Lavín A, José Manuel Olmos, José Manuel Cifrian, Teresa Gimenez, Marco Antonio Gandarillas, Mar García-Saiz, Maria Henar Rebollo, Victor Martínez-Taboada, Marcos López-Hoyos, María Carmen Fariñas, Javier Crespo. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. *Trials* 2020; 21:472
 64. Cuadrado A, Cobo M, Mateo M, Blasco AJ, Cabezas J, Llerena S, Fortea JI, Lázaro P, Crespo J, Telemedicine efficiently improves access to Hepatitis C management to achieve HCV elimination in the penitentiary setting. *International Journal of Drug Policy* 2020; in press.
 65. A, Cuadrado A, Del Pozo C, García I, Pellon R, Cagigal ML, Fábrega E, Crespo J. An elusive diagnosis in non-cirrhotic chronic portal vein thrombosis. *Am J Med.* 2020 Sep 17:S0002-9343(20)30800-7. doi: 10.1016/j.amjmed.2020.07.039. Online ahead of print.
 66. García MJ, Pascual M, Pozo C, Díaz-González A, Castro B, Rasines L, Crespo J, Rivero M. IMPACT OF IMMUNE-MEDIATED DISEASES IN INFLAMMATORY BOWEL DISEASE AND IMPLICATIONS IN THERAPEUTIC APPROACH. *Sci Rep.* 2020 Jul 1;10(1):10731. doi: 10.1038/s41598-020-67710-2.
 67. Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R R, Crespo J J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. *Liver Int.* 2020 Jun 19. doi: 10.1111/liv.14571. Online ahead of print. PMID: 32559006
 68. Olmos-Martínez JM, Hernández JL, Fábrega E, Olmos JM, Crespo J, González-Macías J. Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection. *Arch Osteoporos.* 2020; 15(1): 72. doi: 10.1007/s11657-020-00752-1.PMID: 32399944
 69. Razavi H, Blach S, Razavi-Shearer D. The case for simplifying and using absolute targets for viral hepatitis elimination goals. *Polaris Observatory Collaborators (Cabezas J, Crespo J).* *Liv International* 2020 in press. doi: 10.1111/jvh.13412
 70. Simon J, Nuñez-García M, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X, Lopitz-Otsoa F, Goikoetxea-Usandizaga N, Serrano-Macia M, Rodríguez-Agudo R, Bizkarguenaga M, Zubiete-Franco I, Gutiérrez-de Juan V, Cabrera D, Alonso C, Iruzubieta P, Romero-Gomez M, van Liempd S, Castro A, Nogueiras R, Varela-Rey M, Falcón-Pérez JM, Villa E, Crespo J, Lu SC, Mato JM, Aspichueta P, Delgado TC, Martínez-Chantar ML. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. *Cell Metab.* 2020 Mar 3;31(3):605-622.e10. doi: 10.1016/j.cmet.2020.01.013. Epub 2020 Feb 21.PMID: 32084378
 71. Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, Streinu-Cercel A, Bourgeois S, Buti M, Crespo J, Pascasio JM, Sarrazin C, Vanwolleghem T, Shukla U, Fry J, Yogaratnam JZ. JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection. *Gastroenterology.* 2020 Apr 25:S0016-5085(20)30519-9. doi: 10.1053/j.gastro.2020.04.036.

72. Fortea JI, Puente Á, Cuadrado A, Huelin P, Pellón R, González Sánchez FJ, Mayorga M, Cagigal ML, García Carrera I, Cobreros M, Crespo J, Fábrega E. Congestive Hepatopathy. *Int J Mol Sci.* 2020 Dec 10;21(24):9420. doi: 10.3390/ijms21249420. PMID: 33321947; PMCID: PMC7764741.
73. Cuadrado A, Cobo C, Mateo M, Blasco AJ, Cabezas J, Llerena S, Fortea JI, Lázaro P, Crespo J. Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. *Int J Drug Policy.* 2020 Nov 19;88:103031. doi: 10.1016/j.drugpo.2020.103031. Epub ahead of print. PMID: 33221615.
74. Crespo J, Fernández Carrillo C, Iruzubieta P, Hernández-Conde M, Rasines L, Jorquera F, Albillos A, Bañares R, Mora P, Fernández Vázquez I, Hernández-Guerra M, Turnes J, Calleja JL; COVID-19 SEPD/AEEH Group. Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. *J Gastroenterol Hepatol.* 2020 Nov 12. doi: 10.1111/jgh.15340. Epub ahead of print. PMID: 33184937.
75. Fortea JI, Cuadrado A, Puente Á, Álvarez Fernández P, Huelin P, Álvarez Tato C, García Carrera I, Cobreros M, Cagigal Cobo ML, Calvo Montes J, Ruiz de Alegría Puig C, Rodríguez SanJuan JC, Castillo Suescun FJ, Fernández Santiago R, Echeverri Cifuentes JA, Casafont F, Crespo J, Fábrega E. Is Routine Prophylaxis Against *Pneumocystis jirovecii* Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain. *J Clin Med.* 2020 Nov 6;9(11):3573. doi: 10.3390/jcm9113573. PMID: 33171962; PMCID: PMC7694638.
76. Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández- Hernández MA, López-Hoyos M, Muñoz-Cacho P, Olmos JM, Gutiérrez-Cuadra M, Ruiz- Cubillán JJ, Crespo J, Martínez-Taboada VM. Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection. *J Clin Endocrinol Metab.* 2020 Oct 27:dga733. doi: 10.1210/clinem/dga733. Epub ahead of print. PMID: 33159440; PMCID: PMC7797757.
77. Martínez-Taboada VM, López-Hoyos M, Crespo J, Hernández JL. COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse? *Autoimmun Rev.* 2020 Dec;19(12):102683. doi: 10.1016/j.autrev.2020.102683. Epub 2020 Oct 27. PMID: 33127600; PMCID: PMC7588795.
78. Fondevila MF, Mercado-Gómez M, Rodríguez A, Gonzalez-Rellan MJ, Iruzubieta P, Valentí V, Escalada J, Schwaninger M, Prevot V, Dieguez C, Crespo J, Frühbeck G, Martinez-Chantar ML, Nogueiras R. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. *J Hepatol.* 2020 Oct 20;74(2):469–71. doi: 10.1016/j.jhep.2020.09.027. Epub ahead of print. PMID: 33096086; PMCID: PMC7574841.
79. Crespo J, Díaz-González Á, Iruzubieta P, Llerena S, Cabezas J. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. *J Hepatol.* 2020 Oct 9:S0168-8278(20)33679-5. doi: 10.1016/j.jhep.2020.10.001. Epub ahead of print. PMID: 33039405; PMCID: PMC7544696.
80. Martínez-Taboada VM, López-Hoyos M, Crespo J, Cacho PM, Hernández JL. Thoughts From the Trenches: Should We Look at the "Healthy"? *Front Public Health.* 2020 Sep 9;8:490. doi: 10.3389/fpubh.2020.00490. PMID: 33014980; PMCID: PMC7510210.
81. Polaris Observatory Collaborators. The case for simplifying and using absolute targets for viral hepatitis elimination goals. *J Viral Hepat.* 2021 Jan;28(1):12-19. doi: 10.1111/jvh.13412. Epub 2020 Nov 4. PMID: 32979881.
82. Calleja-Panero JL, Andrade RJ, Bañares R, Crespo J, Esteban R, Jarque I, Mingot-Castellano ME, Romero-Gómez M, Muñoz-Peñín R, Bentley R, Shepherd J, Gil Aguirre A. Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. *Rev Esp Enferm Dig.* 2020 Oct;112(10):778-783. doi: 10.17235/reed.2020.6895/2020. PMID: 32954777.
83. Fortea JI, Carrera IG, Puente Á, Cuadrado A, Huelin P, Tato CÁ, Fernández PÁ, Montes MDRP, Céspedes JN, López AB, Sanchez FJG, Hoyos ML, Crespo J, Fábrega E. Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders. *J Clin Med.* 2020 Aug 31;9(9):2822. doi: 10.3390/jcm9092822. PMID: 32878264; PMCID: PMC7565723.
84. Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (*J Hepatol*

- 2020; 73: 17-25). *J Hepatol*. 2020 Sep;73(3):740-741. doi: 10.1016/j.jhep.2020.06.018. Epub 2020 Jul 9. Erratum for: *J Hepatol*. 2020 Jul;73(1):17-25. PMID: 32654856.
85. Crespo J, Tejerina Puente A, Cuadrado A, Llerena S, Cabezas J; Grupo de Trabajo para la Eliminación de la Hepatitis C en Cantabria. Strategy for the Elimination of Hepatitis C in Cantabria. *Rev Esp Enferm Dig*. 2020 Jul;112(7):565-570. doi: 10.17235/reed.2020.7108/2020. PMID: 32543873.
 86. Hinojosa Del Val J, Crespo J, Pérez-Cuadrado Martínez E. Author's answer to: "Effect of adacolumn® in ulcerative colitis with COVID-19". *Rev Esp Enferm Dig*. 2020 Jun;112(6):511-512. doi: 10.17235/reed.2020.7188/2020. PMID: 32496123.
 87. Cuadrado-Lavín A, Olmos JM, Cifrian JM, Gimenez T, Gandarillas MA, García- Saiz M, Rebollo MH, Martínez-Taboada V, López-Hoyos M, Fariñas MC, Crespo J. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4. PMID: 32493494; PMCID: PMC7268173.
 88. Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. *Enferm Infecc Microbiol Clin*. 2020 May 22:S0213-005X(20)30173-7. English, Spanish. doi: 10.1016/j.eimc.2020.03.004. Epub ahead of print. PMID: 32451150.
 89. Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. *J Clin Med*. 2020 May 7;9(5):1369. doi: 10.3390/jcm9051369. PMID: 32392712; PMCID: PMC7291163.
 90. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet*. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Erratum in: *Lancet*. 2020 Aug 1;396(10247):312. PMID: 31813633.
 91. Puente A, Fortea JI, Del Pozo C, Huelin P, Cagigal ML, Serrano M, Cabezas J, Arias Loste MT, Iruzubieta P, Cuadrado A, Llerena S, Lopez C, Fábrega E, Crespo J. Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. *Cells*. 2019 Nov 24;8(12):1506. doi: 10.3390/cells8121506. PMID: 31771307; PMCID: PMC6952805.
 92. Crespo J, Cuadrado A, Perelló C, Cabezas J, Llerena S, Llorca J, Cedillo S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Lazarus JV, Calleja JL. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. *J Viral Hepat*. 2020 Apr;27(4):360-370. doi: 10.1111/jvh.13238. Epub 2019 Dec 6. PMID: 31755634.
 93. Vázquez-Bourgon J, Ortiz-García de la Foz V, Suarez-Pereira I, Iruzubieta P, Arias-Loste MT, Setién-Suero E, Ayesa-Arriola R, Gómez-Revuelta M, Crespo J, Crespo Facorro B. Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. *Data Brief*. 2019 Oct 25;27:104415. doi: 10.1016/j.dib.2019.104415. PMID: 31737751; PMCID: PMC6849149.
 94. Dalgic OO, Samur S, Spaulding AC, Llerena S, Cobo C, Ayer T, Roberts MS, Crespo J, Chhatwal J. Improved Health Outcomes from Hepatitis C Treatment Scale- Up in Spain's Prisons: A Cost-Effectiveness Study. *Sci Rep*. 2019 Nov 14;9(1):16849. doi: 10.1038/s41598-019-52564-0. PMID: 31727921; PMCID: PMC6856347.
 95. Fernández-Tussy P, Fernández-Ramos D, Lopitz-Otsoa F, Simón J, Barbier- Torres L, Gomez-Santos B, Nuñez-García M, Azkargorta M, Gutiérrez-de Juan V, Serrano-Macia M, Rodríguez-Agudo R, Iruzubieta P, Anguita J, Castro RE, Champagne D, Rincón M, Elortza F, Arslanow A, Krawczyk M, Lammert F, Kirchmeyer M, Behrmann I, Crespo J, Lu SC, Mato JM, Varela-Rey M, Aspichueta P, Delgado TC, Martínez-Chantar ML. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. *Mol Metab*. 2019 Nov;29:40-54. doi: 10.1016/j.molmet.2019.08.008. Epub 2019 Aug 16. PMID: 31668391; PMCID: PMC6728756.

96. Crespo J, Albillos A, Buti M, Calleja JL, García Samaniego J, Hernández Guerra M, Serrano T, Turnes J, Acín E, Berenguer J, Berenguer M, Colom J, Fernández I, Fernández Rodríguez C, Forns X, García F, Grandados R, Lazarus J, Molero JM, Molina E, Pérez Escanilla F, Pineda JA, Rodríguez M, Romero M, Roncero C, Saiz de la Hoya P, Sánchez Antolín G. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). *Rev Esp Enferm Dig.* 2019 Nov;111(11):862-873. doi: 10.17235/reed.2019.6700/2019. PMID: 31657609.
97. Fortea JI, Fernandez González M, Samaniego Vega L, Puente Á, Cuadrado A, Cabezas J, Llerena S, Sáez López A, Crespo J, Fábrega E. Epidemiology and clinical course of hepatitis A in Cantabria before and after the epidemic outbreak of June 2016. *Rev Clin Esp.* 2020 Oct;220(7):400-408. English, Spanish. doi: 10.1016/j.rce.2019.08.005. Epub 2019 Oct 10. PMID: 31606120.
98. Crespo J, Albillos A, Buti M, Calleja JL, García-Samaniego J, Hernández- Guerra M, Serrano T, Turnes J, Acín E, Berenguer J, Berenguer M, Colom J, Fernández I, Fernández Rodríguez C, Forns X, García F, Rafael Granados, Lazarus JV, Molero JM, Molina E, Pérez Escanilla F, Pineda JA, Rodríguez M, Romero M, Roncero C, Saiz de la Hoya P, Sánchez Antolín G. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). *Gastroenterol Hepatol.* 2019 Nov;42(9):579-592. English, Spanish. doi: 10.1016/j.gastrohep.2019.09.002. Epub 2019 Oct 5. PMID: 31594683.
99. Crespo J, Andrade RJ. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth. *Rev Esp Enferm Dig.* 2019 Oct;111(10):727-730. doi: 10.17235/reed.2019.6594/2019. PMID: 31566408.
100. Calleja Panero JL, Lens García S, Fernández Bermejo M, Crespo J. Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. *Rev Esp Enferm Dig.* 2019 Oct;111(10):731-737. doi: 10.17235/reed.2019.6169/2019. PMID: 31526012.
101. Puente A, Fortea JI, Posadas M, Garcia Blanco A, Rasines L, Cabezas J, Arias Loste MT, Llerena S, Iruzubieta P, Fábrega E, Crespo J. Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. *J Clin Med.* 2019 Aug 17;8(8):1242. doi: 10.3390/jcm8081242. PMID: 31426495; PMCID: PMC6723423.
102. Guiral S, Segundo DS, Irure J, Casafont F, Fortea JI, Puente Á, López-Hoyos M, Crespo J, Fabrega E. Number of Antibody-verified Eplet in HLA-C Locus as an Independent Factor of T-cell-Mediated Rejection After Liver Transplantation. *Transplantation.* 2020 Mar;104(3):562-567. doi: 10.1097/TP.0000000000002921. PMID: 31403556.
103. García F, Aguilera A, Crespo J, Pineda JA. In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it? *Enferm Infecc Microbiol Clin.* 2020 Feb;38(2):95. English, Spanish. doi: 10.1016/j.eimc.2019.07.001. Epub 2019 Aug 2. PMID: 31383373.
104. Alarcón Linares ME, Torres Cantero A, Subirá C, Ramírez Rubio O, Crespo J, Lazarus JV, Requena-Méndez A. Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropriate? *Rev Esp Enferm Dig.* 2019 Aug;111(8):615-625. doi: 10.17235/reed.2019.6117/2018. PMID: 31317761.
105. Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, Medina-Cáliz I, Sanabria-Cabrera J, Sanjuan-Jiménez R, González- Jiménez A, García-Cortés M, Lucena MI, Andrade RJ, Robles-Díaz M. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. *United European Gastroenterol J.* 2019 Jul;7(6):825-837. doi: 10.1177/2050640619840147. Epub 2019 Mar 24. PMID: 31316787; PMCID: PMC6620870.
106. Durán-Vian C, Arias-Loste MT, Hernández JL, Fernández V, González M, Iruzubieta P, Rasines L, González-Vela C, Vaqué JP, Blanco R, Crespo J, González-López MA. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. *J Eur Acad Dermatol Venereol.* 2019 Nov;33(11):2131-2136. doi: 10.1111/jdv.15764. Epub 2019 Jul 22. PMID: 31260574.
107. Arias-Loste MT, Iruzubieta P, Crespo J. Paediatric non-alcoholic fatty liver disease: a more complex disease than in the adulthood? *Hepatobiliary Surg Nutr.* 2019 Jun;8(3):270-273. doi: 10.21037/hbsn.2018.12.16. PMID: 31245411; PMCID: PMC6561892.
108. Vázquez-Bourgon J, Ortiz-García de la Foz V, Suarez-Pereira I, Iruzubieta P, Arias-Loste MT, Setién-Suero E, Ayesa-Arriola R, Gómez-Revuelta M, Crespo J, Crespo Facorro B. Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first

- episode non-affective psychosis patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019 Dec 20;95:109677. doi: 10.1016/j.pnpbp.2019.109677. Epub 2019 Jun 20. PMID: 31228640.
109. Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPamet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. *Clin Gastroenterol Hepatol*. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11. PMID: 31195161.
 110. Llerena S, Cabezas J, Cuadrado A, Manuel Olmos J, González M, García F, Cobo C, Crespo J. Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. *Ann Hepatol*. 2019 Jan-Feb;18(1):236-239. doi: 10.5604/01.3001.0012.7931. PMID: 31113598.
 111. Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, Aguilera Guirao A, García-Samaniego Rey J, Eiros Bouza JM, Luis Calleja Panero J, García F. Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. *Enferm Infecc Microbiol Clin*. 2019 Apr;37(4):231-238. English, Spanish. doi: 10.1016/j.eimc.2018.05.016. Epub 2018 Jul 7. PMID: 30929668.
 112. Nistal E, Sáenz de Miera LE, Ballesteros Pomar M, Sánchez-Campos S, García-Mediavilla MV, Álvarez-Cuenllas B, Linares P, Olcoz JL, Arias-Loste MT, García-Lobo JM, Crespo J, González-Gallego J, Jorquera Plaza F. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. *Rev Esp Enferm Dig*. 2019 Apr;111(4):275-282. doi: 10.17235/reed.2019.6068/2018. PMID: 30810328.
 113. Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, Simón MA. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. *Eur J Gastroenterol Hepatol*. 2019 Feb;31(2):267-271. doi: 10.1097/MEG.0000000000001289. PMID: 30576297.
 114. Crespo J, Eiros Bouza JM, Blasco Bravo AJ, Lázaro de Mercado P, Aguilera Guirao A, García F, García-Samaniego Rey J, Calleja Panero JL. The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. *Rev Esp Enferm Dig*. 2019 Jan;111(1):10-16. doi: 10.17235/reed.2018.5810/2018. PMID: 30561219.
 115. Fortea JI, Puente Á, Ruiz P, Ezcurra I, Vaquero J, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J. Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. *World J Clin Cases*. 2018 Nov 6;6(13):611-623. doi: 10.12998/wjcc.v6.i13.611. PMID: 30430116; PMCID: PMC6232571.
 116. Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste MT, Crespo J, Darwish-Murad S, Ikram MA, Olynyk JK, Gan E, Petta S, Berzuini A, Prati D, de Lédinghen V, Wong VW, Del Poggio P, Chávez-Tapia NC, Chen YP, Cheng PN, Yuen MF, Das K, Chowdhury A, Caballería L, Fabrellas N, Ginès P, Kumar M, Sarin SK, Conti F, Andreone P, Sirlì R, Cortez-Pinto H, Carvalhana S, Sugihara T, Kim SU, Parikh P, Chayama K, Corpechot C, Kim KM, Papatheodoridis G, Alsebaey A, Kamath PS, Murad MH, Watt KD. Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. *Clin Gastroenterol Hepatol*. 2019 Jan;17(1):54-64.e1. doi: 10.1016/j.cgh.2018.08.069. Epub 2018 Sep 7. PMID: 30196155.
 117. Fortea JI, Puente Á, Ezcurra I, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J. Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. *Dig Liver Dis*. 2019 Jan;51(1):95-103. doi: 10.1016/j.dld.2018.06.003. Epub 2018 Jun 12. PMID: 29960901.